Tatva Chintan Pharma Chem Limited (IN:TATVA)
:TATVA
Top Page
Tatva Chintan Pharma Chem Limited
(TATVA)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹1,174.00
▼(-15.44% Downside)
Action:ReiteratedDate:01/24/26
The score is held back primarily by weak technical momentum (price below key moving averages with negative MACD) and expensive valuation (very high P/E with minimal dividend yield). Financial performance is mixed: balance sheet strength helps, but profitability volatility and negative free cash flow materially reduce overall quality.
Positive Factors
Diverse end markets
Serving multiple industrial end markets creates demand diversification and reduces reliance on any single cyclical sector. This structural exposure to pharmaceuticals, petrochemicals and energy storage supports stable long-term revenue potential as different end markets follow distinct cycles and secular trends.
Negative Factors
Negative free cash flow
Persistent negative free cash flow driven by heavy capex constrains liquidity and forces reliance on external funding or equity to finance investments. Over months this can pressure reserves, limit strategic optionality, and increase vulnerability if revenue or margins weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Diverse end markets
Serving multiple industrial end markets creates demand diversification and reduces reliance on any single cyclical sector. This structural exposure to pharmaceuticals, petrochemicals and energy storage supports stable long-term revenue potential as different end markets follow distinct cycles and secular trends.
Read all positive factors
Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹24.58B
Dividend Yield0.07%
Average Volume (3M)12.52K
Price to Earnings (P/E)51.4
Beta (1Y)1.06
Revenue Growth16.88%
EPS Growth0.69%
CountryIN
Employees689
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)6.80
Shares Outstanding23,392,056
10 Day Avg. Volume25,333
30 Day Avg. Volume12,516
Financial Highlights & Ratios
PEG Ratio-3.55
Price to Book (P/B)2.24
Price to Sales (P/S)4.33
P/FCF Ratio-32.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.73
Revenue Forecast (FY)₹6.51B
Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model
Company Description
Tatva Chintan Pharma Chem Limited manufactures and sells specialty chemicals in India. The company offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor batteries; ...
How the Company Makes Money
Tatva Chintan Pharma Chem Limited generates revenue through the production and sale of a wide array of fine chemicals and intermediates, primarily targeting the pharmaceutical and agrochemical sectors. Its revenue model hinges on the manufacturing...
Tatva Chintan Pharma Chem Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.34B | 3.83B | 3.94B | 4.24B | 4.34B | 3.00B |
| Gross Profit | 2.22B | 1.84B | 2.11B | 1.91B | 2.32B | 1.43B |
| EBITDA | 567.40M | 342.13M | 689.34M | 676.30M | 1.08B | 666.37M |
| Net Income | 177.36M | 57.13M | 303.54M | 454.87M | 958.74M | 522.62M |
Balance Sheet | ||||||
| Total Assets | 9.08B | 8.36B | 8.19B | 7.56B | 6.58B | 3.15B |
| Cash, Cash Equivalents and Short-Term Investments | 178.47M | 117.01M | 456.68M | 412.15M | 638.19M | 53.24M |
| Total Debt | 830.13M | 363.88M | 142.71M | 1.70B | 1.20B | 902.48M |
| Total Liabilities | 1.53B | 974.25M | 816.36M | 2.42B | 1.85B | 1.49B |
| Stockholders Equity | 7.54B | 7.39B | 7.37B | 5.15B | 4.73B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | -426.18M | -516.01M | -304.71M | -1.75B | -687.79M | 33.49M |
| Operating Cash Flow | 133.81M | 246.71M | 980.44M | 277.83M | 203.78M | 243.19M |
| Investing Cash Flow | -577.76M | -652.54M | -1.21B | -1.01B | -1.97B | -207.02M |
| Financing Cash Flow | 457.32M | 165.66M | 305.19M | 377.95M | 2.35B | -44.80M |
Tatva Chintan Pharma Chem Limited Technical Analysis
Negative
1388.35
Price Trends
1191.77
Negative
1304.68
Negative
1185.32
Negative
Market Momentum
-24.71
Positive
35.39
Neutral
15.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Negative. The current price of 1388.35 is above the 20-day moving average (MA) of 1142.64, above the 50-day MA of 1191.77, and above the 200-day MA of 1185.32, indicating a bearish trend. The MACD of -24.71 indicates Positive momentum. The RSI at 35.39 is Neutral, neither overbought nor oversold. The STOCH value of 15.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TATVA.
Tatva Chintan Pharma Chem Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹21.96B | 23.71 | ― | 0.65% | -10.12% | -22.38% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹21.35B | 29.38 | ― | 0.97% | 5.74% | 16.06% | |
57 Neutral | ₹20.22B | 0.22 | ― | ― | -22.04% | -58.81% | |
56 Neutral | ₹10.87B | 26.88 | ― | 0.24% | 10.70% | 32.65% | |
53 Neutral | ₹24.58B | 51.39 | ― | 0.07% | 16.88% | 0.69% | |
52 Neutral | ₹15.13B | 95.28 | ― | 0.03% | 11.74% | -64.13% |
* Basic Materials Sector Average
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,050.90
325.27
44.83%
IN:FCL
Fineotex Chemical Limited
19.17
-4.39
-18.63%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
72.75
10.21
16.32%
IN:KIRIINDUS
Kiri Industries Limited
336.80
-304.40
-47.47%
IN:PUNJABCHEM
Punjab Chemicals & Crop Protection Ltd.
886.15
-110.93
-11.13%
IN:YASHO
Yasho Industries Ltd.
1,254.45
-492.51
-28.19%
Tatva Chintan Pharma Chem Limited Corporate Events
Tatva Chintan Publishes Q3 FY26 Earnings Call Transcript for Investor Access
Jan 24, 2026
Tatva Chintan Pharma Chem Limited has released the transcript of its Q3 FY26 earnings conference call held on 21 January 2026, following the announcement of its financial results for the quarter and nine months ended 31 December 2025. The company ...
Tatva Chintan Pharma Chem Schedules Investor Meeting with Sequent Investments
Nov 22, 2025
Tatva Chintan Pharma Chem Limited has announced a scheduled virtual meeting with Sequent Investments on November 26, 2025. This meeting is part of the company’s ongoing investor relations efforts, where they will discuss publicly available i...
Tatva Chintan Pharma Chem Clarifies Share Price Movement Amid Market Conditions
Oct 24, 2025
Tatva Chintan Pharma Chem Limited addressed recent price movements in its shares, attributing them to market conditions rather than undisclosed material events. The company assured stakeholders of its compliance with regulatory disclosure requirem...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.